Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/6412
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorPoplavsky, J.L.-
dc.date.accessioned2007-12-20T16:07:42Z-
dc.date.available2007-12-20T16:07:42Z-
dc.date.issued1995-
dc.identifier.citationBlood coagulation and fibrinolysis, 6. p. S86-S92-
dc.identifier.urihttp://hdl.handle.net/1942/6412-
dc.language.isoen-
dc.publisherLippincott Williams & Wilkins-
dc.titleClinical evaluation of virus safety and inhibitor incidence: statistical considerations-
dc.typeJournal Contribution-
dc.identifier.epageS92-
dc.identifier.spageS86-
dc.identifier.volume6-
dc.bibliographicCitation.oldjcat-
item.accessRightsClosed Access-
item.contributorBUYSE, Marc-
item.contributorPoplavsky, J.L.-
item.fullcitationBUYSE, Marc & Poplavsky, J.L. (1995) Clinical evaluation of virus safety and inhibitor incidence: statistical considerations. In: Blood coagulation and fibrinolysis, 6. p. S86-S92.-
item.fulltextNo Fulltext-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.